All News
The RheumNow Week in Review - 16 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.
Read ArticleOpportunistic Infections in RA Rare with Biologics
The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics.
Read ArticleCARES Study- More CV Deaths with Febuxostat
The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.
Read ArticleThe RheumNow Week in Review - 9 March 2018
Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.
Read ArticleFDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis
Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.
Read ArticleBiologics in Pregnancy: Are They Safe?
Exposure to biologic therapies among women with autoimmune diseases was not associated with increased risks of preterm delivery or having small for gestational age babies, a population-based Canadian study found.
Read ArticleDSB – Safety Updates & Drug Shortages – March 2018
This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages.
Read ArticleOpioid Overdoses Jump 30% in 2017
The CDC released new information yesterday showing that emergency department (ED) visits for opioid overdoses rose 30% in the US from July 2016 through September 2017; in addition, those with an overdose are more likely to a repeat overdose.
Read ArticleAbatacept Efficacy in JIA
Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.
Read ArticleSevere Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept
The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T
Read ArticleThe RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read ArticleSteroid Use During Rheumatoid Pregnancies
Pregnant women (n=254) with rheumatoid arthritis who enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study and who were taking oral glucocorticoids were studied.
Read ArticleInflammatory Arthritis Variants with Checkpoint Inhibitors
Capelli and colleagues have studied patients treated with ICIs and found two variants of inflammatory arthritis (IA) - a reactive arthritis like large joint arthritis with combination ICI therapy or a small joint IA with ICI monotherapy.
Read Article2017 Rheumatology Year in Review
This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017. In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.
Read ArticleIL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).
Read ArticleProbenecid Benefits Heart Failure
In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation.
Read ArticleThe RheumNow Week in Review - 23 February 2018
Dr Jack Cush reviews highlights from the past week on RheumNow.com. This week’s video is in two parts; for part Ii, go to https://buff.ly/2BM9MjL
Read ArticleOral Anticoagulation Effective Following Hip and Knee Replacement Surgery
Many protocols call for anticoagulation after total hip or total knee arthroplasty to prevent venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism), and some reports have suggested a role for aspiring or direct oral anticoagulants as preventative therapy. The NEJM has reported that oral anticoagulation with rivaroxaban (Xarelto) followed by aspirin to be effective prophylaxis.
Read ArticleEqual Cardiovascular Risks in Hypertensive Patients Treated with Selective and Nonselective NSAIDS
A Taiwanese study of 55,629 hypertensive patients shows no increased risk of major cardiovascular events comparing outcomes of patients started on COX-2 selective NSAIDs compared with nonselective NSAIDs (including ibuprofen, diclofenac and naproxen).
Read ArticleASCO/NCCN Guidelines for Checkpoint Inhibitor Immune-Related Adverse Events
New guidelines have been developed by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) on how to assess and manage of immune checkpoint inhibitor side effects that are often autoimmune in nature.
Read Article


